Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2021-06-09 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Group of companies' accounts made up to 2020-12-31
Regulatory Filings
2021-06-09 English
Appointment of new Chief Executive Officer
Board/Management Information Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number : 1064A) on May 28, 2021, detailing the 'Appointment of new Chief Executive Officer'. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific content is about management change, making MANG the most precise classification over the general RNS fallback.
2021-05-28 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (3797 characters) and its primary content is an announcement titled 'Total Voting Rights Update' issued via 'RNS Number : 1076A' on '28 May 2021'. It explicitly states the total number of issued shares (215,885,024) for the purpose of FCA Disclosure and Transparency Rule 5.6.1, which is a regulatory disclosure requirement. This type of announcement, which updates a specific regulatory metric (total voting rights) and is distributed via the RNS system, does not fit neatly into the specific financial report categories (like 10-K, IR, ER). Since it is a formal regulatory announcement distributed through the London Stock Exchange's news service (RNS), and it is not a report itself, the most appropriate classification is the general regulatory announcement category, RNS.
2021-05-28 English
US update
Regulatory Filings Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date (21 May 2021) and company information, typical of a regulatory news service announcement. The content provides an update on US launch preparations for a product, detailing operational capabilities, marketing, sales force, medical affairs, and market access progress. This is a general corporate update disseminated via the Regulatory News Service (RNS). Since it is not a full financial report (like 10-K or IR), a specific announcement like an Earnings Release (ER), or a notice of a specific event like a dividend (DIV) or director dealing (DIRS), it fits best into the general regulatory announcement category, which is RNS.
2021-05-21 English
AEGIS-H2H study results published in IBD
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number (8680Y) and the date (18 May 2021). The content describes the publication of study results (AEGIS-H2H) in a journal ('Inflammatory Bowel Diseases') concerning the company's product, ferric maltol. It provides details about the study, quotes the lead author, and includes contact information. Crucially, the footer explicitly states: "This information is provided by Reach, the non-regulatory press release distribution service of RNS... Reach announcements are identified with an orange label and the word “Reach" in the source column..." This indicates it is a general press release or announcement that is not a core regulatory filing like a 10-K, IR, or ER, but rather a general update distributed via the RNS platform. Since it is a non-regulatory announcement about a scientific/clinical update, and it doesn't fit specific categories like DIV, DIRS, or MANG, the most appropriate general category for non-core regulatory news distributed via RNS is 'Regulatory Filings' (RNS) as the fallback for miscellaneous announcements, although 'LTR' (Legal Proceedings Report) might seem plausible if the publication was mandated by a legal settlement, but here it is a voluntary publication of study results. Given the context of a press release distributed via the RNS system that isn't a core financial report, RNS is the best fit among the provided options for a general announcement.
2021-05-18 English
Commencement of trading on the OTCQX Best Market
Delisting Announcement Classification · 99% confidence The document begins with an 'RNS Number' header and contains information about a company (Shield Therapeutics plc) announcing that its shares will begin trading on the OTCQX Best Market in the United States. This is a general corporate announcement related to market listing and investor access, not a specific financial report (like 10-K, IR, ER) or a formal regulatory filing like a Director's Dealing or Proxy Statement. The presence of the RNS Number and the nature of the announcement (market access/listing update) strongly suggest it falls under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a miscellaneous, non-specific corporate update distributed via the London Stock Exchange's news service.
2021-05-17 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.